TMCnet - World's Largest Communications and Technology Community


TMCNET eNEWSLETTER SIGNUP Stocks That Stand Out For Nov. 20th, 2009 Are RFMD, GETA, CLDS, HESG
[November 20, 2009] Stocks That Stand Out For Nov. 20th, 2009 Are RFMD, GETA, CLDS, HESG

Nov 20, 2009 (M2 PRESSWIRE via COMTEX) -- Stocks That Standout For Nov. 20th, 2009 are RF Micro Devices, Inc. (Nasdaq: RFMD), Genta Incorporated (OTCBB: GETA), Celestial Delights USA Corp. (OTCBB: CLDS), Health Sciences Group, Inc. (Pink Sheets: HESG) Visit Us On Twitter and Facebook: Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "" _________________________________________________ RFMD(R) Selected by Leading Smartphone Manufacturer to Supply High Performance Cellular Switch RFMD'S RF1130 Designed Into Two CDMA Smartphones to be Introduced in 2010 GREENSBORO, N.C., Nov 19, 2009 -- RF Micro Devices, Inc. (Nasdaq:RFMD), a global leader in the design and manufacture of high-performance RF components and compound semiconductors, today announced that RFMD has been selected by a leading manufacturer of smartphones to support two upcoming CDMA smartphones.

RFMD will supply its high performance RF1130 single-pole 3-throw (SP3T) cellular switch into two upcoming models targeting the consumer smartphone market. The first device is expected to launch in the first half of calendar 2010, and shipments of the RF1130 are expected to commence in the March 2010 quarter.

Mike DeHaan, general manager of RFMD's Switch and Signal Conditioning business unit, said, "We are pleased to support this leading smartphone manufacturer with our RF1130 cellular switch, and we look forward to expanding our relationship through additional design opportunities across our RF Components and Switch and Signal Conditioning product portfolios. As new 3G/4G air interface standards are added and cellular devices increase in RF complexity, our expanding product portfolio and wide technology base enable RFMD to uniquely satisfy the technical requirements of tomorrow's smartphones and battery-powered multimedia devices." The design win is expected to support RFMD's diversification efforts across customers and air interface standards. RFMD is engaged at this leading smartphone manufacturer to secure incremental business opportunities across 3G front ends, cellular switches, RF power management and WLAN components.

RFMD enjoys a leading share in smartphones and expects its revenue growth in smartphones in calendar 2010 will significantly exceed the rate of growth of the handset market.

About RFMD RF Micro Devices, Inc. (Nasdaq:RFMD) is a global leader in the design and manufacture of high-performance radio frequency components and compound semiconductor technologies. RFMD's products enable worldwide mobility, provide enhanced connectivity and support advanced functionality in the cellular handset, wireless infrastructure, wireless local area network (WLAN), CATV/broadband and aerospace and defense markets. RFMD is recognized for its diverse portfolio of semiconductor technologies and RF systems expertise and is a preferred supplier to the world's leading mobile device, customer premises and communications equipment providers.

Headquartered in Greensboro, N.C., RFMD is an ISO 9001- and ISO 14001-certified manufacturer with worldwide engineering, design, sales and service facilities. RFMD is traded on the NASDAQ Global Select Market under the symbol RFMD. For more information, please visit RFMD's web site at

The RF Micro Devices, Inc. logo is available at // This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements included herein represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those expressed or implied by forward-looking statements. We do not intend to update any of these forward-looking statements or publicly announce the results of any revisions to these forward-looking statements, other than as is required under the federal securities laws. RF Micro Devices' business is subject to numerous risks and uncertainties, including risks associated with the impact of global macroeconomic and credit conditions on our business and the business of our suppliers and customers, variability in operating results, the rate of growth and development of wireless markets, risks associated with the reduced investment in our wireless systems business, our ability to execute on our plans to consolidate or relocate manufacturing operations, our reliance on inclusion in third party reference designs for a portion of our revenue, our ability to manage channel partner and customer relationships, risks associated with the operation of our wafer fabrication facilities, molecular beam epitaxy facility, assembly facility and test and tape and reel facilities, our ability to complete acquisitions and integrate acquired companies, including the risk that we may not realize expected synergies from our business combinations, our ability to attract and retain skilled personnel and develop leaders, variability in production yields, raw material costs and availability, our ability to reduce costs and improve margins in response to declining average selling prices, our ability to bring new products to market, our ability to adjust production capacity in a timely fashion in response to changes in demand for our products, dependence on a limited number of customers, dependence on gallium arsenide (GaAs) for the majority of our products, and dependence on third parties. These and other risks and uncertainties, which are described in more detail in RF Micro Devices' most recent Annual Report on Form 10-K and other reports and statements filed with the Securities and Exchange Commission, could cause actual results and developments to be materially different from those expressed or implied by any of these forward-looking statements.

Genasense(R) Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma Data Presented at International Melanoma Conference in Berlin BERKELEY HEIGHTS, N.J., Nov 20, 2009 -- --Results Follow Decision by Company to Continue Phase 3 AGENDA Trial for Overall Survival Genta Incorporated (OTCBB: GETA.OB) announced preliminary results that show a high objective response rate in a pilot study of patients with advanced melanoma that incorporates the Company's lead oncology product, Genasense(R) (oblimersen sodium) Injection, administered for the first time as a 1-hour high-dose intravenous (IV) infusion. The data were featured this week in a presentation at the annual World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in Berlin, Germany.

Based on preclinical evidence of synergy, this study combined Genasense with temozolomide (Temodar(R); Schering Plough, Inc.), the most commonly used anticancer drug for melanoma, and Abraxane(R) (paclitaxel protein-bound particles for injectable suspension [albumen bound]; Abraxis Bioscience, Inc.). Previous results using a standard dose and schedule of Genasense (i.e., approximately 500 mg infused over 24 hours daily for 7 days) suggested this investigational combination was associated with clinical activity and good tolerability in 18 patients.

In the new schedule, Genasense was administered with the same chemotherapy as a brief IV infusion over 1-hour twice per week for 4 consecutive weeks at a dose of 900 mg. This schedule compresses approximately 48 hours of standard dosing into a brief 1-hour infusion.

To date, 10 patients with Stage IV metastatic melanoma have been accrued to this ongoing trial. Three patients achieved confirmed partial responses after the first 2 treatment cycles with current durations lasting from 24 to 40 weeks. One patient has maintained stable disease that has lasted 16 weeks, two patients have progressed, and four patients are too early to evaluate, having received only a single cycle. Only one episode (i.e., Grade 3 neutropenia) of any Grade 3-4 adverse event has been observed.

"With a preliminary disease control rate (defined as complete or partial responses plus stable disease lasting at least 3 months) of 67%, we view these data as very promising," said Dr. Loretta M. Itri, Genta's President, Pharmaceutical Development. "Temozolomide is the active metabolite of dacarbazine that has been used in our Phase 3 trial in patients with advanced melanoma. I am pleased to confirm that Genta will continue the Phase 3, randomized, double-blind AGENDA trial in order to determine overall survival in that study. Finally, taxanes are being increasingly used in patients with metastatic melanoma. We intend to initiate a Phase 2 study of our proprietary oral taxane, tesetaxel, in advanced melanoma. We hope our comprehensive approach with these new medicines may improve the management of this devastating disease." About the AGENDA trial in advanced melanoma Genta has completed enrollment into AGENDA, a Phase 3, randomized, double-blind, placebo-controlled trial of Genasense in patients with advanced melanoma. Initial results did not show statistically significant differences in overall response or progression-free survival. The endpoints of durable response (complete or partial response lasting greater-than or equal to 6 months) and overall survival are too early to evaluate. An analysis for futility has been conducted for the survival endpoint, and the trial has passed that analysis. The Company has announced it plans to continue to follow patients on AGENDA in order to determine this endpoint.

About the World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers This international conference is organized annually by the European Association of Dermatologic Oncology (EADO), which is a co-leader of the AGENDA trial. The meeting offers melanoma clinicians and researchers from multidisciplinary melanoma/skin cancer centers an opportunity to interact, establish collaborations, and set an agenda for the further evolution of melanoma care and research. Genta is a Co-Sponsor of the EADO meeting.

About Melanoma Malignant melanoma is the most deadly form of skin cancer. The incidence of this disease is increasing by approximately 4% annually in the U.S. Melanoma is the number one cause of cancer death in women aged 25 to 29. More information about melanoma can be accessed at the Melanoma Research Foundation:

About Genasense Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta has pursued a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense is being developed as an agent that may enhance the effectiveness of current anticancer therapy. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed oral formulations of the active ingredient in Ganite, which have completed preliminary clinical trials, as a potential treatment for diseases associated with accelerated bone loss. The Company is developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Genta intends to evaluate the clinical activity of tesetaxel in a range of human cancers. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at:

Safe Harbor This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially", "anticipate", "could", "calls for", and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with: -- the Company's ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency; -- the safety and efficacy of the Company's products or product candidates; -- the commencement and completion of any clinical trials; -- the Company's assessment of its clinical trials; -- the Company's ability to develop, manufacture, license, or sell its products or product candidates; -- the Company's ability to enter into and successfully execute any license and collaborative agreements; -- the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, the Company's ability to obtain sufficient financing to fund the AGENDA trial, or the Company's risk of bankruptcy; -- the adequacy of the Company's patents and proprietary rights; -- the impact of litigation that has been brought against the Company; and -- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2008 and its most recent quarterly report on Form 10-Q.

Celestial Delights USA Corp. Appoints Director -- Company Takes Aim at Asia PHOENIX, AZ, Nov 19, 2009 -- Celestial Delights USA Corp. (OTCBB: CLDS) (the "Company") is pleased to announce the appointment of Mr. Marcus Laun as a member of the Board of Directors.

Mr. Laun is currently a senior banker at Wynston Hill Capital, LLC where he is responsible for all aspects of capital raising and advisory engagements for micro- and small-cap ventures. Since May 2009 he has been a Director with GC China Turbine Corp. From 2004 through 2008, Mr. Laun held various senior positions at Knight Capital Group of New York. From 2000-2004, Mr. Laun was founder and chief executive officer of Hype (USA) Inc. which controlled the exclusive rights to HYPE Energy Drink in North America. Prior to this, Mr. Laun was a vice president of corporate finance at Brean Murray & Co., Inc. and a research analyst at Greenwich High Yield LLC and Mendham Capital Group LLC. Mr. Laun received a Master's in Business Administration degree from Columbia Business School and received a Bachelor of Science degree from Cornell University.

Celestial Delights appreciates Mr. Laun's invaluable expertise, knowledge and participation as the Company moves towards the development of strategic business interests in Asia.

Details of this appointment can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

Notice Regarding Forward-Looking Statements This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Health Sciences Group Quest to be Listed on the OTCBB INDIAN HARBOUR BEACH, Fla., Nov 19, 2009 -- Health Sciences Group, Inc. (Pink Sheets:HESG) would like to announce that its lawyer Mr. Robert Young is aggressively seeking realtors in the Los Angeles area to open up Health Sciences offices. The company intends on pursuing with new consultant agreement under Marijuana Inc. a joint venture to market management services. "We are still in negotiations with Marijuana Inc. (MJNA) to complete a joint venture or merger or rolling up into a reporting OTCBB shell. We have all intentions of bringing on the best legal team possible and to make medical marijuana acceptable to the public. I can not say it enough -- we are not about legalizing pot for recreational purposes-we are against it! We are here for the millions of ill people that could and will greatly benefit from medical marijuana. I have first hand experience with medical marijuana and it works, it eases pain, anxiety, and increases appetite. I witnessed it first hand with the passing of my own father. This is personal to me," said Thomas Gaffney, President and CEO of Health Sciences Group, Inc.

Gaffney continues, "As far as the companies are concerned, we are in preliminary talks about moving to the OTCBB to provide transparency to the public. Health Sciences' chief priority is sustainable economic success -- a priority shared by all of our employees and management and by me especially. By providing the best possible transparency into our business by joining forces with Medical Marijuana, Inc. and other medical marijuana based companies, this will give us the growth and strength to increase shareholder value. Health Sciences will continue to operate and our magazine iGoHealthy." We would appreciate any shareholders opinion or ideas at ABOUT HEALTH SCIENCES GROUP, INC.

Health Sciences Group, Inc. is a provider of health and wellness services to consumers, physicians and other healthcare professionals through its website,, and health focused publications. The Health Sciences network consists of its public website,, and iGoHealthy Magazine. The Company operates in three segments: Online Services, Publishing and Other Services. The Company is recently exploring options of corporate growth within the Legal Medical Marijuana Industry.

FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Health Sciences Group, Inc. to be materially different from the statements made herein.

About has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at and select the "join now" button.

Join us at for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. profiles are not a solicitation or recommendation to buy, sell or hold securities. is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), is owned and operated by Neither nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in statements and opinions and such statements and opinions cannot be considered independent. and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. services are often paid for using free-trading shares. may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: CONTACT: Jason A. Hilton, Standout Stocks Tel: +1 585 729 8809 e-mail: e-mail: ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at on the world wide web. Inquiries to

[ Back To's Homepage ]

Technology Marketing Corporation

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA
Ph: +1-203-852-6800, 800-243-6002

General comments:
Comments about this site:


© 2020 Technology Marketing Corporation. All rights reserved | Privacy Policy